The Prenylation Inhibitor Lonafarnib (LNF) Can Induce Post-Treatment Viral Clearance in Patients with Chronic Hepatitis Delta (CDH) Resulting in ALT Normalization and Regression of Fibrosis: Summary of Observations from Individual Cases: Retreatment with Lonafarnib in a Subset of HDV-Infected Patients

C. YURDAYDIN1, R. IDILMAN1, C. KALKAN1, F. KARAKAYA1, A. CALISKAN1, O. KESKIN1, E. YURDCU1, S. Karatayli1, A. M. Bozdayi1, C. Koh2, T. Heller2, J. S. Glenn3

Division of Gastroenterology, University of Ankara Medical School, Ankara, Turkey; Liver Diseases Branch, National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland; Division of Gastroenterology and Hepatology, Stanford University School of Medicine. *These authors share senior authorship.

1. Abstract

Background and Aims: CDH is the most severe form of viral hepatitis, with no adequate therapy. The prenylation inhibitor LNF is the first investigational agent targeted for hepatitis D virus (HDV). Here we report the post-treatment clearance and subsequent follow-up course in patients who were HDV-RNA positive following treatment with 12-24 weeks of LNF.

Methods: 27 patients were analyzed who had detectable end of treatment HDV-RNA after receiving LNF for 12-24 weeks in the LOWR HDV-1 and LOWR HDV-2 (Lonafarnib With Ritonavir for HDV-1 and 2) trials, and who were at least 24 weeks post-treatment. A post-treatment ALT flare was defined as elevation of ALT to >2x baseline (BL) level.

Results: Patients came from multiple LNF treatment cohorts: LNF 200 mg BID, 12 weeks; LNF 300 mg BID, 12 weeks; LNF 100 mg BID + RTV 50 mg BID, 12 weeks; LNF 75 mg BID + RTV 100 mg BID, 12 weeks, followed by addition of pegylated interferon alpha, 12 weeks; LNF 50 mg BID + RTV 100 mg BID, 24 weeks. Following treatment, 5 of 27 (18.5%) patients experienced post-treatment ALT flares (median ALT 190 U/mL, range 110-1355 U/mL), resulting in ALT normalization and HDV-RNA negativity within 12-24 weeks. In all 5 patients, HDV-RNA had declined rapidly during LNF treatment, followed by gradual rises on-therapy to near BL levels, associated with decreased LNF exposure (due to dose reductions or excessive GI side effects). HBV DNA levels increased in all 5 patients by at least 3 logs (none had received concomitant nucleoside analog treatment). Post-flare HBV DNA levels were suppressed in all 5 patients (>1000 IU/mL) and undetectable in 2 patients. HBsAg in one patient decreased from 3900 IU/mL to <10 IU/mL. Two patients with intermittent low level HDV-RNA (BLOQ) post-ALT flare were retreated with 24 weeks low dose LNF (LNF 50 mg BID + RTV). HDV-RNA PCR-negativity was achieved soon after re-starting treatment, and has remained so to date >12 weeks post-ending re-treatment. Fibrosis grade decreased compared to BL from 4 to 3, 2 to 0 and 6 to 4, respectively, in the 3 patients rebiopsied 6-18 months following initial HDV-RNA normalization and HDV-RNA negativity.

Conclusions: LNF can induce therapeutic post-treatment immunological flares—a phenomenon heretofore not described in CDH. Thus, at least two pathways for achieving HDV negativity with LNF therapy exist: LNF-induced progressive suppression to HDV negativity on-treatment, and LNF-induced post-treatment anti-HDV therapeutic flares.

2. Background – Hepatitis Delta (HDV)

HDV leads to the most severe form of viral hepatitis

- More rapid progression to liver cirrhosis
- More likely to develop HCC / decompensation vs HBV

- HDV is always associated with HBV Infection

- HDV steals HBsAg from HBV for envelopment

- HDV hijacks prenylation, a host process

- HDV worldwide prevalence is 15 - 20 million

- No FDA approved Rx for HDV

- HDV hijacks prenylation, a host process

- HDV steals HBsAg from HBV for envelopment

- More likely to develop HCC / decompensation vs HBV

- HDV leads to the most severe form of viral hepatitis

- HDV hijacks prenylation, a host process

- HDV steals HBsAg from HBV for envelopment

- HDV leads to the most severe form of viral hepatitis

- HDV hijacks prenylation, a host process

- HDV steals HBsAg from HBV for envelopment

- More likely to develop HCC / decompensation vs HBV

3. Background: Lonafarnib (LNF)

- Lonafarnib is a small molecule, oral, prenylation inhibitor
- Well-characterized through Phase 3
  - >20,000 patients dosed in oncology program by Merck
- Dose limiting toxicity is GI (class effect)
- Prenylation is a host target; potential high barrier to resistance
- LOWR HDV (Lonafarnib With Ritonavir in HDV) Program
  - Identify dose and regimen for registration study
  - Over 120 HDV patients dosed across 3 international sites

4. Background: LOWR HDV – 1 and LOWR HDV – 2 Study

Purpose:

To identify combination regimens of LNF and RTV + PEG IFNα which demonstrate efficacy and tolerability for longer term dosing to enable HDV-RNA clearance

Observations:

- LNF suppresses HDV-RNA < LOQ at end of treatment
- ALT normalizes in majority of patients at end of treatment
- Subset of patients who do not clear HDV-RNA on-treatment have become HDV-RNA negative post-treatment

5. Post-Treatment Analysis in LOWR HDV -1 and LOWR HDV - 2

- 27 patients were analyzed who had detectable HDV-RNA after receiving LNF for 12 or 24 weeks in the LOWR HDV-1 and LOWR HDV-2 trials
- 5 patients identified with post-treatment ALT flares followed by HDV-RNA negativity
- 2 of 5 patients with HDV-RNA rebound were re-treated with low dose LNF
- Testing frequency: Q4W
  - Biochemical parameters and HBV DNA
  - HDV-RNA (by in-house qPCR with LOQ ~ 3 log copies/mL)

6. Results: Re-treatment with Low Dose LNF-regimen Drives HDV-RNA to PCR-negativity

HDV-RNA Negative for 24 Weeks Post-Retreatment

<table>
<thead>
<tr>
<th>LNF 200 mg BID</th>
<th>LNF 50 mg BID + RTV 100 mg BID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-treatment ALT flares</td>
<td></td>
</tr>
</tbody>
</table>

HDV-RNA Negative for 24 Weeks Post-Retreatment

<table>
<thead>
<tr>
<th>LNF 300 mg BID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-treatment ALT flares</td>
</tr>
</tbody>
</table>

7. Conclusions

Summary of Observations from Individual Cases:

- Post-treatment ALT flares observed in some LNF-treated HDV patients
- Post-treatment ALT flares are followed by:
  - Normalizing ALT levels
  - Sustained HDV-RNA negativity
  - HDV-RNA < LOQ, alternating with negativity
- Re-treatment with LNF 50 mg BID + RTV 100 mg BID for 6 months:
  - Rapid achievement of HDV-RNA negativity on re-treatment
  - HDV-RNA negativity sustained throughout re-treatment
  - HDV-RNA negativity sustained > 6 months post-treatment
- Long term ALT normalization has resulted in reversal of fibrosis

- LNF was provided by Eiger Biopharmaceuticals, Inc. Equity interest in Eiger Biopharmaceuticals, Inc. Yurdaydin: Received partial travel support from Eiger Biopharmaceuticals, Inc. to attend scientific meetings. All other authors have no financial disclosures.